“But GSK is showing strength elsewhere in its portfolio with 19% growth ... settlement to resolve tens of thousands of lawsuits in the US over its discontinued heartburn drug Zantac earlier in October ...

And with no admitted fault or failure, I'm delighted that we've also drawn a line under the vast majority of Zantac litigation ... our antibody drug conjugate for extensive stage small-cell ...

Sanofi's existing product line boasts several top-tier drugs, including immunology drug Dupixent ... related to the increasingly concerning Zantac litagation. Overall, we rate Sanofi’s ...

“But GSK is showing strength elsewhere in its portfolio with ... of lawsuits in the US over its discontinued heartburn drug Zantac earlier in October.

So why would GSK, the largest of the four major distributors of the now-recalled stomach acid drug, suddenly abandon the tried-and-true defense mantra, “millions for defense, not a penny for tribute”?

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...